Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 1, 1999, Pages 23-27

  Angeletti, S ^a   Corleto, V D ^a   Schillaci, O ^a   Moretti, A ^a   Panzuto, F ^a   Annibale, B ^a   Delle Fave, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gastro entero pancreatic endocrine tumours; Octreotide

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOCRINE TUMOR; FEMALE; GALLSTONE; GASTRINOMA; GASTROINTESTINAL TUMOR; HUMAN; INJECTION PAIN; MALE; METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; SCINTIGRAPHY; TUMOR GROWTH; ZOLLINGER ELLISON SYNDROME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTRINOMA; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0032938731     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. th edition, Philadelphia: WB Saunders, 1993:1695-721.
2. Jensen RT. Pancreatic endocrine tumours. Curr Opin Gastroenterol 1995;11:423-9.
3. Metz DC. Diagnosis and treatment of pancreatic neuroendocrine tumors. Sem Gastroint Dis 1995;6:67-78.
4. Eriksson B, Öberg K. Interferon therapy of malignant endocrine pancreatic tumors. In Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Frontiers in gastrointestinal research. Basel: Karger, 1995;23:451-60.
5. Scarpignato C. Somatostatin analogues in the management of endocrine tumors of the pancreas. In: Mignon M, Jensen RT, editors. Endocrine tumours of the pancreas. Frontiers in gastrointestinal research. Basel: Karger, 1995;23:385-414.
6. Kraenzlin ME, Ch'ng JLC, Wood SM, Carr DH, Bloom SR. Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985;88:185-7.
7. van Eijk CH, Sloder GD, Hofland LJ, Jeekel WK, Lamberts SW, Marquet RT. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg 1994,81:1333-7.
8. Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996;81:677-83.
9. Annibale B, Delle Fave G, Azzoni C, Corleto VD, Camboni G, D'Ambra G, et al. Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction. Aliment Pharmacol Ther 1994;8:95-104.
10. Corleto VD, Scopinaro F, Angeletti S, Materia A, Basso N, Polettini E, et al. Somatostatin receptor localization of pancreatic endocrine tumors. World J Surg 1996;38:241-4.
11. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998;42:792-4.
12. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol (Copenh) 1985;109:108-14.
13. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin
14. and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 1991;12:450-82.
15. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analogue SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991;129:2555-61.
16. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 1988;114:306-8.
17. Shepherd JJ, Senator GB. Regression of liver metastases in patients with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986;2:574.
18. Arnold R, Trautmann ME, Creutzfeldt TW, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996;38:430-8.
19. Saltz I, Trochanowsky B, Buckley M, Heffernan B, Niedzwic-ki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993;72:244-8.
20. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996;77:402-8.
21. Eriksson B, Öberg K, Andersson T, Lundqvist G, Wide L, Wilander E. Treatment of malignant endocrine pancreatic tumors with a new long acting somatostatin analogue SMS 201-995. Scand J Gastroenterol 1988;23:508-12.
22. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Boese-Landgraf J, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-9.
23. Kubota A, Yamada Y, Kagimoto S. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5.